69 related articles for article (PubMed ID: 35437311)
1. Safety analysis of patients who received ruxolitinib for steroid-refractory acute or chronic graft-versus-host disease in an expanded access program.
Schroeder MA; Hari PN; Blithe A; Paranagama D; Bhatt V; DiPersio JF
Bone Marrow Transplant; 2022 Jun; 57(6):975-981. PubMed ID: 35437311
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety in Early application of Ruxolinitib for high-risk: Acute lymphoblastic leukemia to prevent GVHD and recurrence after allogeneic hematopoietic stem cell transplantation.
Cheng Q; Tang Y; Liu F; Li X; Fang D
Transpl Immunol; 2024 Apr; 83():101978. PubMed ID: 38302005
[TBL] [Abstract][Full Text] [Related]
3. ANZTCT consensus position statement on ruxolitinib in steroid-refractory acute and chronic graft-versus-host disease.
Hamad N; Bilmon I; Chee L; Henden A; Johnston A; Purtill D; Bajel A; Tey SK; Yeung D; Cole T; Lewis C; Butler J
Intern Med J; 2023 Dec; 53(12):2319-2329. PubMed ID: 38014511
[TBL] [Abstract][Full Text] [Related]
4. Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH trials.
Jagasia M; Zeiser R; Arbushites M; Delaite P; Gadbaw B; Bubnoff NV
Immunotherapy; 2018 Apr; 10(5):391-402. PubMed ID: 29316837
[TBL] [Abstract][Full Text] [Related]
5. Ruxolitinib versus basiliximab for steroid-refractory acute graft-versus-host disease: a retrospective study.
Liu J; Fan Z; Xu N; Ye J; Chen Y; Shao R; Sun Y; Wu Q; Liu Q; Jin H
Ann Hematol; 2023 Oct; 102(10):2865-2877. PubMed ID: 37474631
[TBL] [Abstract][Full Text] [Related]
6. Ruxolitinib in patients with graft versus host disease (GvHD): findings from a compassionate use program.
Pattipaka T; Sarp S; Nakhaei P; Güneş S
Bone Marrow Transplant; 2024 May; 59(5):637-646. PubMed ID: 38361117
[TBL] [Abstract][Full Text] [Related]
7. When is the best time and grade to start ruxolitinib in corticosteroid-refractory acute graft-versus-host-disease: A multi-center research.
Ren J; Lin K; Xu J; Lu Q; Luo Y; Lin C; Lu J; Weng Y; Zhang Y; Chen Z; Gale RP; Hu J; Yang T
Clin Transplant; 2024 Jan; 38(1):e15195. PubMed ID: 37987525
[TBL] [Abstract][Full Text] [Related]
8. ECP versus ruxolitinib in steroid-refractory chronic GVHD - a retrospective study by the EBMT transplant complications working party.
Penack O; Peczynski C; Boreland W; Lemaitre J; Reinhardt HC; Afanasyeva K; Avenoso D; Holderried TAW; Kornblit BT; Gavriilaki E; Martinez C; Chiusolo P; Mico MC; Dagunet E; Wichert S; Ozdogu H; Piekarska A; Kinsella F; Basak GW; Schoemans H; Koenecke C; Moiseev I; Peric Z
Bone Marrow Transplant; 2024 Mar; 59(3):380-386. PubMed ID: 38184740
[TBL] [Abstract][Full Text] [Related]
9. Ruxolitinib for the treatment of acute and chronic graft-versus-host disease in children: a systematic review and individual patient data meta-analysis.
Baccelli F; Gottardi F; Muratore E; Leardini D; Grasso AG; Gori D; Belotti T; Prete A; Masetti R
Bone Marrow Transplant; 2024 Jun; 59(6):765-776. PubMed ID: 38402346
[TBL] [Abstract][Full Text] [Related]
10. Janus kinase inhibition in the treatment and prevention of graft-versus-host disease.
De Togni E; Cole O; Abboud R
Front Immunol; 2024; 15():1304065. PubMed ID: 38380328
[TBL] [Abstract][Full Text] [Related]
11. Novel therapies for graft versus host disease with a focus on cell therapies.
Zeiser R; Ringden O; Sadeghi B; Gonen-Yaacovi G; Segurado OG
Front Immunol; 2023; 14():1241068. PubMed ID: 37868964
[TBL] [Abstract][Full Text] [Related]
12. Tongue graft-versus-host disease: remission with ruxolitinib.
Grafanaki K; Lygeros S; Spyridonidis A; Liga M
BMJ Case Rep; 2022 May; 15(5):. PubMed ID: 35606043
[TBL] [Abstract][Full Text] [Related]
13. Ruxolitinib Pharmacokinetics and Pharmacodynamics in Children with Acute and Chronic Graft-versus-Host Disease.
Cook E; Dong M; Chiang SCC; Luedeke D; Lake KE; Hoerth C; Deavy M; Setchell KDR; Zhao J; Punt N; Galletta T; Teusink-Cross A; Davies SM; Marsh RA; Mehta P; Khandelwal P
Transplant Cell Ther; 2024 May; 30(5):528.e1-528.e12. PubMed ID: 38401793
[TBL] [Abstract][Full Text] [Related]
14. Effect of ruxolitinib on the oral mucosa of patients with steroid-refractory chronic Graft-versus-Host disease and oral involvement.
Kaurinovic M; Delli K; Jonk AE; Biswana A; Hazenberg CLE; Choi G; de Groot MR; Morsink LM; Vissink A; Bellido M
Clin Oral Investig; 2022 May; 26(5):4209-4216. PubMed ID: 35169886
[TBL] [Abstract][Full Text] [Related]
15. Tocilizumab combined with ruxolitinib in the treatment of children with steroid resistant graft versus host disease after hematopoietic stem cell transplantation: report of 6 cases.
Chen J; Lu J; Hong X; Lu Q
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 51(4):470-473. PubMed ID: 37202101
[TBL] [Abstract][Full Text] [Related]
16. Ruxolitinib add-on therapy in steroid-refractory graft-vs-host disease following hematopoietic cell transplantation: A single institutional experience.
Wang YL; Chang TY; Wen YC; Yang SH; Hsiao YW; Chen SH; Jaing TH
Pediatr Neonatol; 2024 Jan; 65(1):85-86. PubMed ID: 37951828
[No Abstract] [Full Text] [Related]
17. Ruxolitinib as the first post-steroid treatment for acute and chronic graft-versus-host disease.
Algeri M; Becilli M; Locatelli F
Expert Rev Clin Immunol; 2023; 19(11):1299-1313. PubMed ID: 37606511
[TBL] [Abstract][Full Text] [Related]
18. Current and Emerging Targeted Therapies for Acute Graft-Versus-Host Disease.
Kasikis S; Etra A; Levine JE
BioDrugs; 2021 Jan; 35(1):19-33. PubMed ID: 33201499
[TBL] [Abstract][Full Text] [Related]
19. Topical ruxolitinib is promising as sole or adjunctive therapy in treating maculopapular rash of acute and chronic skin GVHD.
Hudda Z; Flannery A; Teusink-Cross A; Davies SM; Khandelwal P
Bone Marrow Transplant; 2024 Mar; 59(3):425-427. PubMed ID: 38182673
[No Abstract] [Full Text] [Related]
20. Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial.
Teshima T; Onishi Y; Kato K; Taniguchi S; Miyamura K; Fukushima K; Kato J; Ishikawa T; Doki N; Nakamae H; Maeda Y; Inamoto Y; Okada M; Maki A; Shimada F; Tajima T; Wroclawska M; Zeiser R; Onizuka M
Int J Hematol; 2024 May; ():. PubMed ID: 38796666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
